Tuberculosis Clinical Trial
Official title:
A Phase 1, Partially-Blinded, Placebo-Controlled, Randomized, Single Ascending Dose (SAD) With a Food Effect Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adult Participants.
Verified date | March 2021 |
Source | Global Alliance for TB Drug Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Partially-Blinded, Placebo-Controlled, Randomized, Single Ascending Dose (SAD) with a Food Effect Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults.
Status | Completed |
Enrollment | 91 |
Est. completion date | March 14, 2020 |
Est. primary completion date | February 22, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 19 Years to 50 Years |
Eligibility | Inclusion Criteria: All volunteers must satisfy the following criteria to be considered for study participation: 1. Understands study procedures and voluntarily provides written informed consent prior to the start of any study-specific procedures. 2. Is a healthy adult male or a healthy adult female of non-childbearing potential, 19 to 50 years of age (inclusive) at the time of screening. 3. Has a body mass index (BMI) =18.5 and =32.0 (kg/m2) and a body weight of no less than 50.0 kg. 4. Is medically healthy with no clinically significant screening results, as determined by the Principal Investigator (e.g., laboratory profiles are normal up to and including Grade 1 per DMID toxicity tables; Appendix 3), medical history, vital signs, ECG, or physical/neurological examination findings. Note: If exclusionary lab criteria are met, values may be confirmed by repeat evaluation. 5. Has not used tobacco- or nicotine-containing products (including smoking cessation products), for a minimum of 6 months before dosing. 6. If female, she has undergone one of the following sterilization procedures at least 6 months before dosing: - Hysteroscopic sterilization; - Bilateral tubal ligation or bilateral salpingectomy; - Hysterectomy; or - Bilateral oophorectomy; - Or is postmenopausal with amenorrhea for at least 1 year before the first dose with serum follicle-stimulating hormone (FSH) levels consistent with postmenopausal status (i.e., greater than 40 mIU/mL) at screening. - Or, if female of childbearing potential, must agree to use an allowable form of birth control from screening until 14 days after study completion. The following are allowed birth control methods for this study: - Vasectomized partner (at least 6 months before dosing); - Non-surgical permanent sterilization (e.g., Essure procedure) at least 3 months before dosing; - Double barrier method (e.g., diaphragm with spermicide; condoms with spermicide); - Intrauterine device (IUD); - Abstinence (and must agree to use a double barrier method if they become sexually active during the study); - Implanted or intrauterine hormonal contraceptives in use for at least 6 consecutive months before study dosing; and/or - Oral, patch, or injected contraceptives, or vaginal hormonal device (NuvaRing), in use for at least 3 consecutive months before study dosing. 7. If a non-vasectomized male (or male vasectomized less than 120 days prior to study start) he must agree to the following during study participation and for 90 days after the last administration of study drug: - Use a condom with spermicide while engaging in sexual activity or be sexually abstinent, - Not donate sperm during this time. In the event the sexual partner is surgically sterile or postmenopausal, use of a condom with spermicide is not necessary. None of the birth control restrictions listed above are required for vasectomized males whose procedure was performed more than 120 days before study start. 8. Is willing to answer inclusion and exclusion criteria questionnaire at check-in. 9. Is able to comply with the protocol and the assessments therein, including all restrictions. 10. Is willing and able to remain in the study unit for the entire duration of the assigned confinement period(s), return for outpatient visit(s), and receive a phone call for follow-up questioning about AEs. 11. If enrolled in the food-effect cohort, is willing and able to consume the entire high-calorie, high-fat breakfast meal in the timeframe required. Exclusion Criteria: Volunteers will be excluded from study participation for any of the following: 1. History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological (including epilepsy), oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results. 2. Evidence on physical exam and targeted neurologic exam of specific findings such as resting or intention tremor, dysmetria, nystagmus or ataxia, or abnormal deep tendon reflexes (either zero or hyper-reflexia). 3. History of any illness that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk to the subject by their participation in the study. 4. Surgery within the past 90 days prior to dosing as determined by the Investigator to be clinically relevant, or any history of cholecystectomy. 5. History or presence of alcoholism or drug abuse within the past 2 years as determined by the Investigator to be clinically relevant. 6. History of sensitivity or contraindication to use of linezolid, sulfa drugs, or any study investigational products. 7. Participation in another clinical trial within 30 days prior to dosing. 8. Female subjects who are pregnant or lactating. 9. Positive result on a urine drug/alcohol/cotinine screen at Baseline or check-in. 10. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening. Out-of-range vital signs may be repeated once for confirmation. 11. Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening. Out-of-range vital signs may be repeated once for confirmation. 12. Any clinically significant ECG abnormality at Screening (as deemed by decision of the Investigator and the Sponsor's Medical Monitor). NOTE: The following may be considered not clinically significant without consulting the Sponsor's Medical Monitor: - Mild first degree A-V block (P-R interval <0.23 sec) - Right or left axis deviation - Incomplete right bundle branch block - Isolated left anterior fascicular block (left anterior hemiblock) in younger athletic subjects - Early repolarization - Tall T waves - RSR in V1/V2 consistent with right ventricular conduction delay (with acceptable QRS) - Sinus rhythm or sinus bradycardia with sinus arrhythmia - Minimal or moderate voltage criteria for left ventricular hypertrophy (LVH). 13. QTcF interval >450 msec for males or >470 msec for females at screening, Day -1, or Day 1 (pre-dose), or history of prolonged QT syndrome. For the triplicate ECGs taken at screening and on Day -1, the average QTcF interval of the three ECG recordings will be used to determine qualification. 14. Family history of long-QT syndrome or sudden death without a preceding diagnosis of a condition that could be causative of sudden death (such as known coronary artery disease, congestive heart failure, or terminal cancer). 15. History of one or any combination of, the following: - Seizures or seizure disorders, other than childhood febrile seizures - Brain surgery - History of head injury in the last 5 years - Any serious disorder of the central nervous system (CNS) or related neurological system, particularly one that may lower the seizure threshold. 16. Lactose intolerant. 17. History or presence of allergic or adverse response to Listerine breath strips or aspartame. Specific Treatments 18. Use of any prescription medication within 14 days prior to dosing. 19. Use of any of the following medications within 30 days before the first dose of study drug or during the study drug treatment period: monoamine oxidase (MAO) inhibitors (phenelzine, tranylcypromine), tricyclic antidepressants (amitriptyline, nortriptyline, protriptyline, doxepin, amoxapine, etc.), antipsychotics such as chlorpromazine and buspirone, serotonin re-uptake inhibitors (fluoxetine, paroxetine, sertraline, etc.), bupropion, agents known to prolong the QTc interval (erythromycin, clarithromycin, astemizole, type Ia [quinidine, procainamide, disopyramide] and III [amiodarone, sotalol] anti-arrhythmics, carbamazepine, sulfonylureas, and meperidine). 20. Use of any over-the-counter (OTC) medication, including herbal products and vitamins, within 7 days prior to dosing, except acetaminophen. Up to 3 grams per day of acetaminophen is allowed at the discretion of the Investigator prior to dosing. 21. Use of any drugs or substances known to be significant inhibitors of cytochrome P450 (CYP) enzymes and/or significant inhibitors or substrates of P-glycoprotein (P-gp) and/or organic anion transporting polypeptides (OATP) within 14 days prior to the first dose of study drug. 22. Use of any drugs or substances known to be inducers of CYP enzymes and/or Pgp, including St. John's Wort, within 30 days prior to the first dose of study drug. 23. Use of any drugs or substance known to lower the seizure threshold. Laboratory Abnormalities 24. Serum magnesium, potassium, or calcium laboratory values outside of the normal range at screening. If exclusionary lab criteria are met, values may be confirmed by repeat evaluation. 25. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV). |
Country | Name | City | State |
---|---|---|---|
United States | Worldwide Clinical Trials (WCT) | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Global Alliance for TB Drug Development |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with treatment-related and other adverse events as assessed by the Division of Microbiology and Infectious Disease (DMID) Toxicity Table | Safety assessments will include physical and detailed neurological examinations (including assessments of mental status, cranial nerves, motor system, sensory system, reflexes, coordination and gait), vital signs including heart rate and respiratory rate, ECGs, cardiac monitor (Holter monitoring starting 24 hours prior to dose and continuing for 48 hours post dose), collection of all AEs (including treatment- related AEs and SAEs) and clinical laboratory tests (including hematology, serum chemistry, coagulation, and urinalysis prior to dosing and at protocol defined time points up to 72 hours post dose). Subjects will be called 11 days post dose to query for AEs. | Day 1 - Day 4 Post Dose | |
Secondary | Noncompartmental pharmacokinetic parameters of TBI-223 and its metabolite M2 after single doses of TBI-223 using AUClast | AUClast will be calculated from plasma concentrations of TBI-223 and M2. AUClast is area under the concentration-time curve from time-zero to the time of the last quantifiable concentration; calculated using the linear trapezoidal rule. | Day 1 - Day 2 | |
Secondary | Noncompartmental pharmacokinetic parameters of TBI-223 and its metabolite M2 after single doses of TBI-223 using AUCinf | AUCinf will be calculated from plasma concentrations of TBI-223 and M2. AUCinf is area under the concentration-time curve from time-zero extrapolated to infinity. | Day 1 - Day 2 | |
Secondary | Noncompartmental pharmacokinetic parameters of TBI-223 and its metabolite M2 after single doses of TBI-223 using Cmax | Cmax will be calculated from plasma concentrations of TBI-223 and M2. Cmax is maximum concentration, determined directly from individual concentration-time data. | Day 1 - Day 2 | |
Secondary | Noncompartmental pharmacokinetic parameters of TBI-223 and its metabolite M2 after single doses of TBI-223 using Tmax | Tmax will be calculated from plasma concentrations of TBI-223 and M2. Tmax is time of the maximum concentration. | Day 1 - Day 2 | |
Secondary | Noncompartmental pharmacokinetic parameters of TBI-223 after single doses of TBI-223 using CL/F | CL/F will be calculated from plasma concentrations of TBI-223 only. CL/F is apparent total clearance after single administration. | Day 1 - Day 2 | |
Secondary | Noncompartmental pharmacokinetic parameters of TBI-223 after single doses of TBI-223 using Vz/F | Vz/F will be calculated from plasma concentrations of TBI-223 only. Vz/F is apparent volume of distribution in the terminal phase. | Day 1 - Day 2 | |
Secondary | Noncompartmental pharmacokinetic parameters of TBI-223 and its metabolite M2 after single doses of TBI-223 using ?z | ?z will be calculated from plasma concentrations of TBI-223 and M2. ?z is the observed terminal rate constant; estimated by linear regression through at least three data points in the terminal phase of the log concentration-time profile. | Day 1 - Day 2 | |
Secondary | Noncompartmental pharmacokinetic parameters of TBI-223 and its metabolite M2 after single doses of TBI-223 using T1/2 | T1/2 will be calculated from plasma concentrations of TBI-223 and M2. T½ or t½ is the observed terminal half-life. | Day 1 - Day 2 | |
Secondary | Compare the rate and extent of absorption of a single dose of TBI-223 using AUClast, when administered after a high-calorie, high-fat meal versus in fasting state in healthy adult subjects | AUClast will be calculated from plasma concentrations of TBI-223 and M2 with and without high-fat meal. AUClast is area under the concentration-time curve from time-zero to the time of the last quantifiable concentration; calculated using the linear trapezoidal rule. | Day 1 - Day 2 | |
Secondary | Compare the rate and extent of absorption of a single dose of TBI-223 using AUCinf, when administered after a high-calorie, high-fat meal versus in fasting state in healthy adult subjects | AUCinf will be calculated from plasma concentrations of TBI-223 and M2 with and without high-fat meal. AUCinf is area under the concentration-time curve from time-zero extrapolated to infinity. | Day 1 - Day 2 | |
Secondary | Compare the rate and extent of absorption of a single dose of TBI-223 using Cmax, when administered after a high-calorie, high-fat meal versus in fasting state in healthy adult subjects | Cmax will be calculated from plasma concentrations of TBI-223 and M2 with and without high-fat meal. Cmax is maximum concentration, determined directly from individual concentration-time data. | Day 1 - Day 2 | |
Secondary | Compare the rate and extent of absorption of a single dose of TBI-223 using Tmax, when administered after a high-calorie, high-fat meal versus in fasting state in healthy adult subjects | Tmax will be calculated from plasma concentrations of TBI-223 and M2 with and without high-fat meal. Tmax is time of the maximum concentration. | Day 1 - Day 2 | |
Secondary | Compare the rate and extent of absorption of a single dose of TBI-223 using CL/F, when administered after a high-calorie, high-fat meal versus in fasting state in healthy adult subjects | CL/F will be calculated from plasma concentrations of TBI-223 and M2 with and without high-fat meal. CL/F is apparent total clearance after single administration. | Day 1 - Day 2 | |
Secondary | Compare the rate and extent of absorption of a single dose of TBI-223 using Vz/F, when administered after a high-calorie, high-fat meal versus in fasting state in healthy adult subjects | Vz/F will be calculated from plasma concentrations of TBI-223 and M2 with and without high-fat meal. Vz/F is apparent volume of distribution in the terminal phase. | Day 1 - Day 2 | |
Secondary | Compare the rate and extent of absorption of a single dose of TBI-223 using ?z, when administered after a high-calorie, high-fat meal versus in fasting state in healthy adult subjects | ?z will be calculated from plasma concentrations of TBI-223 and M2 with and without high-fat meal. ?z is the observed terminal rate constant; estimated by linear regression through at least three data points in the terminal phase of the log concentration-time profile. | Day 1 - Day 2 | |
Secondary | Compare the rate and extent of absorption of a single dose of TBI-223 using T1/2, when administered after a high-calorie, high-fat meal versus in fasting state in healthy adult subjects | T1/2 will be calculated from plasma concentrations of TBI-223 and M2 with and without high-fat meal. T½ or t½ is the observed terminal half-life. | Day 1 - Day 2 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |